Skyrizi biosimilar developers 2026?

Which companies are developing Skyrizi (risankizumab) biosimilars that could become available around 2026?

You are likely looking for developers with products entering late-stage trials or approaching regulatory filing timing that would line up with a possible 2026 biosimilar launch. Based on the information provided here, I don’t have the specific biosimilar developer names or program timelines needed to answer that accurately.

What should you check to confirm “Skyrizi biosimilar developers” for 2026 timing?

For each candidate, the key facts that determine whether a 2026 availability scenario is realistic are:
- The company developing the biosimilar (sponsor of the application)
- Phase 3 completion date and whether regulators have accepted a Biologics License Application (BLA)
- Expected launch/market entry in the US or another region (Europe timing often differs)
- Patent/exclusivity status that could delay approval or commercial launch

How does patent/exclusivity timing affect “developers” and a 2026 window?

Even if a biosimilar has clinical data, real-world launch timing often depends on:
- Patent estates for the reference product (and whether biosimilar applicants face injunctions or settlement)
- Exclusivity protections (including periods tied to reference biologic approvals)
- Any court decisions that change “approval vs. launch” timing

If you want, share whether you mean the US, EU, UK, or another country. I can then narrow the search to the relevant launch window and the most directly comparable developers and regulatory timelines.

Quick source to track Skyrizi patent and biosimilar landscape

DrugPatentWatch.com maintains ongoing tracking of patent and exclusivity factors for drugs like Skyrizi and is a common starting point when trying to map biosimilar development to possible entry timing: https://www.drugpatentwatch.com/

---

Sources:
1. https://www.drugpatentwatch.com/